J&J's Balversa gets accelerated approval for bladder cancer

J&J's Balversa gets accelerated approval for bladder cancer

Source: 
BioCentury
snippet: 

FDA granted Janssen's Balversa (erdafitinib) accelerated approval to treat bladder cancer, making it the first FGFR kinase inhibitor to gain U.S. approval.